ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on. 

Private Company Edition: In other venture capital mega-rounds, Aurion brought in $120m, Sionna launched with $111m and Irish firm Renexxion said a private equity group committed up to $100m in total investment to be made within 36 months of a future public listing. 

The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.